Charts

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET -

U.S. District Judge Matthew Kacsmaryk questioned President Joe Biden's administration lawyers on whether the federal regulatory ...

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET

Gainers Biophytis (NASDAQ:BPTS) stock moved upwards by 34.1% to $0.56 during Thursday's pre-market session. The company's market cap ...

TheFDA issuedan "import alert" about the animal tranquilizer xylazine, also called "tranq," ...

Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) stock rose 92.8% to $2.28 during Monday's regular session. Cardio Diagnostics Hldgs's ...

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, "Method to Improve Safety and Efficacy of Anti-Cancer Therapy." A patent from the recently allowed application is expected to be issued in the coming months.

- Live video webcast presentations with participating companies -

Live video webcast on Tuesday, January 17th at 10:00 AM ET

Gainers Metacrine (NASDAQ:MTCR) stock increased by 27.0% to $0.45 during Monday's after-market session. Today's trading volume for this ...

During Friday's trading, 293 companies set new 52-week lows. Areas of Significance In Today's 52-Week ...

The performance at Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) has been rather lacklustre of late and shareholders may be...

The performance at Xenetic Biosciences, Inc. ( NASDAQ:XBIO ) has been rather lacklustre of late and shareholders may be...

Gainers Horizon Therapeutics (NASDAQ:HZNP) shares rose 31.8% to $103.8 during Wednesday's pre-market session. The market value of their ...

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% on Tuesday. Fast Radius ...

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company's DNase platform

Xenetic Biosciences ( NASDAQ:XBIO ) Third Quarter 2022 Results Key Financial Results Revenue: US$414.3k (up 19% from 3Q...

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development- Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer

FRAMINGHAM, MA / ACCESSWIRE / October 4, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.

FRAMINGHAM, MA / ACCESSWIRE / September 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Second quarter marked by deal to in-license DNase-based oncology platform which expands pipeline with well-defined and accelerated path to clinic

FRAMINGHAM, MA / ACCESSWIRE / August 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, and VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, today announced a research and development collaboration to develop Neutrophil Extracellular Traps ("NETs") targeted, adoptive cell therapies for the treatment of cancer.

FRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC ("Catalent"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.

- Live video webcast with moderated roundtable with members of the Xenetic leadership team and surgical oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET -

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET

- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities

Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market ...

Gainers T Stamp Inc. (NASDAQ: IDAI) shares surged 123.8% to close at $4.70 on Thursday. Trust Stamp reported the launch of its ...

Gainers T Stamp Inc. (NASDAQ: IDAI) shares jumped 201% to $6.33. Trust Stamp reported the launch of its Biometric Multi-Factor ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're gearing up for another busy day of trading with a breakdown of the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

Gainers T Stamp Inc. (NASDAQ: IDAI) shares rose 103.3% to $4.27 in pre-market trading after gaining over 8% on Wednesday. Trust ...

Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity

- XCARTTM continuing to advance toward IND-enabling studies

Gainers FIGS (NYSE:FIGS) stock rose 11.1% to $15.6 during Tuesday's after-market session. Today's trading volume for this security ...

Tuesday morning saw 454 companies set new 52-week lows. Interesting Facts About Today's 52-Week Lows: Unilever ...

Gainers Black Diamond Therapeutic (NASDAQ:BDTX) stock increased by 18.2% to $5.32 during Tuesday's pre-market ...

Gainers iSpecimen (NASDAQ:ISPC) stock rose 31.09% to $6.45 during Monday's pre-market session. The company's ...

Gainers Bellerophon Therapeutics (NASDAQ:BLPH) shares moved upwards by 8.12% to $3.66 during Thursday's after-market ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Looking for a list of the best short squeeze stocks available? We've got you covered with Fintel's insight into the topic today. The post Short Squeeze Stocks: NAOV, AHPI and 3 Others Experts Think Are Ready to Pop appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar